Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial.


Journal

Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 17 01 2020
pubmed: 3 6 2020
medline: 29 7 2021
entrez: 3 6 2020
Statut: ppublish

Résumé

Multi-morbidity and polypharmacy increase the risk of non-trivial adverse drug reactions (ADRs) in older people during hospitalization. Despite this, there are no established interventions for hospital-acquired ADR prevention. We undertook a pragmatic, multi-national, parallel arm prospective randomized open-label, blinded endpoint (PROBE) controlled trial enrolling patients at six European medical centres. We randomized 1,537 older medical and surgical patients with multi-morbidity and polypharmacy on admission in a 1:1 ratio to SENATOR software-guided medication optimization plus standard care (intervention, n = 772, mean number of daily medications = 9.34) or standard care alone (control, n = 765, mean number of daily medications = 9.23) using block randomization stratified by site and admission type. Attending clinicians in the intervention arm received SENATOR-generated advice at a single time point with recommendations they could choose to adopt or not. The primary endpoint was occurrence of probable or certain ADRs within 14 days of randomization. Secondary endpoints were primary endpoint derivatives; tertiary endpoints included all-cause mortality, re-hospitalization, composite healthcare utilization and health-related quality of life. For the primary endpoint, there was no difference between the intervention and control groups (24.5 vs. 24.8%; OR 0.98; 95% CI 0.77-1.24; P = 0.88). Similarly, with secondary and tertiary endpoints, there were no significant differences. Among attending clinicians in the intervention group, implementation of SENATOR software-generated medication advice points was poor (~15%). In this trial, uptake of software-generated medication advice to minimize ADRs was poor and did not reduce ADR incidence during index hospitalization.

Sections du résumé

BACKGROUND
Multi-morbidity and polypharmacy increase the risk of non-trivial adverse drug reactions (ADRs) in older people during hospitalization. Despite this, there are no established interventions for hospital-acquired ADR prevention.
METHODS
We undertook a pragmatic, multi-national, parallel arm prospective randomized open-label, blinded endpoint (PROBE) controlled trial enrolling patients at six European medical centres. We randomized 1,537 older medical and surgical patients with multi-morbidity and polypharmacy on admission in a 1:1 ratio to SENATOR software-guided medication optimization plus standard care (intervention, n = 772, mean number of daily medications = 9.34) or standard care alone (control, n = 765, mean number of daily medications = 9.23) using block randomization stratified by site and admission type. Attending clinicians in the intervention arm received SENATOR-generated advice at a single time point with recommendations they could choose to adopt or not. The primary endpoint was occurrence of probable or certain ADRs within 14 days of randomization. Secondary endpoints were primary endpoint derivatives; tertiary endpoints included all-cause mortality, re-hospitalization, composite healthcare utilization and health-related quality of life.
RESULTS
For the primary endpoint, there was no difference between the intervention and control groups (24.5 vs. 24.8%; OR 0.98; 95% CI 0.77-1.24; P = 0.88). Similarly, with secondary and tertiary endpoints, there were no significant differences. Among attending clinicians in the intervention group, implementation of SENATOR software-generated medication advice points was poor (~15%).
CONCLUSIONS
In this trial, uptake of software-generated medication advice to minimize ADRs was poor and did not reduce ADR incidence during index hospitalization.

Identifiants

pubmed: 32484850
pii: 5827768
doi: 10.1093/ageing/afaa072
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

605-614

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Denis O'Mahony (D)

University College Cork School of Medicine-Medicine Cork Ireland, Cork University Hospital Group, Cork, Ireland.

Adalsteinn Gudmundsson (A)

Landspitali University Hospital Reykjavik, Landspitali, Iceland.

Roy L Soiza (RL)

NHS Grampian, University of Aberdeen Institute of Applied Health Sciences-Ageing Clinical and Experimental Research, Aberdeen, UK.

Mirko Petrovic (M)

University of Ghent-Medicine, University Hospital Ghent, Ghent, Belgium.

Alfonso Jose Cruz-Jentoft (AJ)

Hospital Universario Ramón y Cajal-Geriatrics, Madrid, Spain.

Antonio Cherubini (A)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Richard Fordham (R)

Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.

Stephen Byrne (S)

School of Pharmacy, University College Cork, Cork, Ireland.

Darren Dahly (D)

University College Cork, Cork, Ireland.

Paul Gallagher (P)

Cork University Hospital-Geriatric Medicine, Cork, Ireland.

Amanda Lavan (A)

University College Cork, School of Medicine-Geriatrics, Cork, Ireland.

Denis Curtin (D)

University College Cork, School of Medicine-Geriatrics, Cork, Ireland.

Kieran Dalton (K)

University College Cork, National University of Ireland, Pharmaceutical Care Research Group, School of Pharmacy, Cork Ireland.

Shane Cullinan (S)

Royal College of Surgeons, School of Pharmacy, Dublin, Ireland.

Evelyn Flanagan (E)

University College Cork, Clinical Research Facility, Cork, Ireland.

Frances Shiely (F)

University College Cork, School of Epidemiology and Public Health, Cork, Ireland.

Olafur Samuelsson (O)

Landspitali University Hospital, Geriatric Medicine Reykjavik, Iceland.

Astros Sverrisdottir (A)

Landspitali University Hospital, Geriatric Medicine Reykjavik, Iceland.

Selvarani Subbarayan (S)

NHS Grampian, Aberdeen Royal Infirmary, Aberdeen UK.

Lore Vandaele (L)

University Hospital Ghent, Ghent, Belgium.

Eline Meireson (E)

University Hospital Ghent, Ghent, Belgium.

Beatriz Montero-Errasquin (B)

Hospital Universario Ramón y Cajal-Geriatrics, Madrid, Spain.

Aurora Rexach-Cano (A)

Hospital Universario Ramón y Cajal-Geriatrics, Madrid, Spain.

Andrea Correa Perez (A)

Hospital Universario Ramón y Cajal-Geriatrics, Madrid, Spain.

Isabel Lozano-Montoya (I)

Hospital Universario Ramón y Cajal-Geriatrics, Madrid, Spain.

Manuel Vélez-Díaz-Pallarés (M)

Hospital Universario Ramón y Cajal-Geriatrics, Madrid, Spain.

Annarita Cerenzia (A)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Samanta Corradi (S)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Maria Soledad Cotorruelo Ferreiro (M)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Federica Dimitri (F)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Paolo Marinelli (P)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Gaia Martelli (G)

Italian National Research Center on Aging (IRCCS-INRCA), Geriatrics and Geriatrics Emergency Care, Ancona, Italy.

Rebekah Fong Soe Khioe (R)

University of East Anglia, Faculty of Medicine and Health Sciences, Norwich, UK.

Joseph Eustace (J)

University College Cork, National University of Ireland-Clinical Research Facility, Cork, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH